Rossari Biotech slips 5% after board approves Rs 300 cr preferential issue

Rossari proposes to utilise the net proceeds to evaluate and invest in inorganic growth opportunities, within its core chemistries, with a view to diversify its product portfolio

Rossari Biotech slips 5% as board approves Rs 300 crore preferential issue

SI Reporter Mumbai
Shares of Rossari Biotech slipped 5 per cent to Rs 1,056.80 on the BSE in intra-day trade on Wednesday on profit booking after the company board gave a go-ahead to issue equity shares aggregating to Rs 300 crore on a preferential basis. The company is a speciality chemicals manufacturer, providing intelligent and sustainable solutions for customers across industries. In the past four trading days, the stock has rallied 14 per cent.

The company said its board of directors approved the issuance of up to 3.01 million equity shares on a preferential basis and determined a floor price of Rs 996 per equity share or such a higher price, aggregating to Rs 300 crore. This preferential issue is subject to necessary approvals,

First Published: Mar 24 2021 | 10:51 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to